Apogenix inks cancer drug development deal for China

Germany's Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize its lead immuno-oncology drug candidate APG101 in ChinaMacao, and Hong Kong. Under the terms of the deal, Apogenix gets an undisclosed upfront and milestone payments as well as double-digit royalty rates following commercial launch of APG101 in China. Release